Cervical cancer is the number one cancer killer of women in sub-Saharan Africa (SSA), with roughly 100,000 women diagnosed annually; of these women, about 62% will die from the disease. Women living with HIV (WLHIV) are up to five times more likely to develop persistent precancerous lesions and progress to cervical cancer, often with more aggressive form and higher mortality.

Launched in May 2018 to address this challenge, Go Further is an innovative public-private partnership between the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR), the George W. Bush Institute, the Joint United Nations Programme on HIV/AIDS (UNAIDS), and Merck. The partnership collaborates closely with governments to strategize on ways to provide services for women from prevention through the cancer journey. Go Further began working in eight countries (Botswana, Eswatini, Lesotho, Malawi, Mozambique, Namibia, Zambia, and Zimbabwe), and will expand services to four additional countries (Ethiopia, Kenya, Tanzania, Uganda) in fiscal year (FY) 2021. The objectives are to screen all WLHIV on ART between the ages of 25 and 49 for cervical cancer, and to treat pre-invasive cervical cancer lesions to prevent progression to cervical cancer.

### Eswatini Program Highlights

<table>
<thead>
<tr>
<th></th>
<th>Funding Amount</th>
<th>WLHIV on Treatment*</th>
<th>Cervical Cancer Screening Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>FY19</td>
<td>$3,700,000</td>
<td>50,000</td>
<td>25,000</td>
</tr>
<tr>
<td>FY20</td>
<td>$1,018,705</td>
<td>79,885</td>
<td>38,713</td>
</tr>
<tr>
<td>FY21</td>
<td>$3,019,062**</td>
<td>79,168</td>
<td>43,024</td>
</tr>
</tbody>
</table>

* For FY19, this is the number of women aged 30+ estimated to be on treatment; otherwise, this is women aged 25–49 on treatment at the end of FYs 18 and 19, respectively. (Source: PEPFAR Panorama Spotlight)

** $1,500,000 of this amount is allocated for an HPV vaccine evaluation

### Country Context

**Total Population**  (July 2020 est.)  
(World Factbook)  
1,104,479

**Women Aged 15–49 HIV Prevalence Rate**  
(UNAIDS 2019)  
34.8%

**Age-standardized Incidence Rate (per 100,000) of Cervical Cancer Cases Attributable to HPV**  
(Estimates for 2018)  
(HPV Information Center)  
75.3

**Total # of Women (All Ages) On ART**  
(PEPFAR, FY20 Q2)  
125,456
Strategic Direction for FY21

- In FY20: 23,016 screenings were done, representing 59% of the FY20 target, and 85% of women who screened positive for precancerous lesions were treated.
- Since FY18: 1,030 women have screened positive for suspected invasive cervical cancer. Of the 56,224 screenings, 40,925 (72.8%) were first time screenings, 485 (0.9%) were follow-up screenings, and 14,814 (26.3%) were re-screens.

In addition to improving laboratory capacity for histopathology services, a partnership with a private laboratory will be solicited to ensure timely availability of histopathology results from LEEP samples and appropriate further management.

Implementing Partners (FY20)
- University Research Corporation
- Trustees of Columbia University in the City of New York
- Population Services International
- The Luke Commission
- Elizabeth Glaser Pediatric AIDS Foundation